On February 23, Wu Zhen, deputy director of the SFDA visited China Health Group innovative base, focusing on the innovative capability of the R&D on new drug. Vice President of China Health Group , Dr. Song Xuemei gave an introduction for the guests on the capability of global pharmaceutical center, mainly on international multi-center clinical trial sample preparation service and the transformation of the Medium-term trial, as well as the R&D progress of sixteen New Drug (¢ñ). Mr. Wu highly appreciated China Health Group for its R&D capability and the operational mode of pharmaceutical value chain and all-round service, Mr. Wu is confident of the future development of China Health Group and hope China Health Group become a world leader in Pharmaceutical industry.
|
